Keyphrases
Non-small Cell Lung Cancer Patients
100%
Concurrent Chemoradiation
100%
Pneumonitis
100%
Durvalumab
100%
Body Mass Index
12%
Progression-free Survival
12%
Clinically Significant
12%
Disease Severity
12%
Overall Survival
12%
Chronic Obstructive Pulmonary Disease
12%
Significant Predictors
12%
Chemotherapy Regimen
12%
Risk of Death
12%
Comorbidity Index
12%
Retrospective Cohort Study
6%
Median Overall Survival
6%
Obesity
6%
Cox Proportional Hazards Model
6%
Logistic Regression Analysis
6%
Kaplan-Meier Method
6%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
6%
Patient Demographics
6%
Cox Proportional Hazard Analysis
6%
Common Terminology Criteria for Adverse Events (CTCAE)
6%
Clinical Predictors
6%
Univariate Logistic Regression
6%
Disease Development
6%
Predictor Variables
6%
Therapy Discontinuation
6%
Real-world Population
6%
PACIFIC Trial
6%
Programmed death-1 Inhibitor
6%
Data Service
6%
VINCI
6%
Immunology and Microbiology
Pneumonitis
100%
Durvalumab
100%
Overall Survival
18%
Progression Free Survival
12%
Body Mass
12%
Comorbidity
12%
Programmed Death 1 Ligand 1
6%